Analysis: Eylea, Lucentis less cost-effective than Avastin for treatment of DME

Aflibercept and ranibizumab were less cost-effective than bevacizumab in the treatment of diabetic macular edema, according to a post hoc analysis of data from the Diabetic Retinopathy Clinical Research Network Protocol T trial.“These results highlight the challenges that physicians, patients and policymakers face when safety and efficacy results are at odds with cost-effectiveness results,” the study authors said.

Early data ‘promising’ for gene therapy for Leber’s hereditary optic neuropathy

GenSight Biologics reported “promising” preliminary data on its gene therapy product for the treatment of neurodegenerative retinal disease, according to a press release.The study included 15 patients with Leber’s hereditary optic neuropathy (LHON) grouped into five groups, with each group of three patients receiving an escalating dose of GS010 via single intravitreal injection in the more severely affected eye. Mean onset of disease was 6 years. Enrollment in the phase 1/2 safety and tolerability study was completed in April 2015.